about
Brain delivery of proteins via their fatty acid and block copolymer modificationsConjugation of insulin onto the sidewalls of single-walled carbon nanotubes through functionalization and diimide-activated amidation.Effects of localized interactions and surface properties on stability of protein-based therapeutics.Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery.Tailoring structure-function properties of L-asparaginase: engineering resistance to trypsin cleavageA multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6 (PEG-rhIL-6) in rats.Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin.Conformational and aggregation properties of a PEGylated alanine-rich polypeptideAgile delivery of protein therapeutics to CNSMultivalent protein polymers with controlled chemical and physical properties.The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorptionPrevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.Universal method for the determination of nonionic surfactant content in the presence of protein.Long-circulating delivery of bioactive polysaccharide from radix ophiopogonis by PEGylationBroadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansionImproving the stability of the EC1 domain of E-cadherin by thiol alkylation of the cysteine residue.Solid-phase synthesis and kinetic characterization of fluorogenic enzyme-degradable hydrogel cross-linkers.PEGylated bioactive molecules in biodegradable polymer microparticles.Nanoparticle strategies for the oral delivery of insulin.Poly(ethylene glycol) hydrogels formed by thiol-ene photopolymerization for enzyme-responsive protein delivery.Supramolecular PEGylation of biopharmaceuticalsDesign of oral insulin delivery systems.Product development issues for PEGylated proteins.Biohybrid block copolymers: towards functional micelles and vesicles.PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes.Is there a future for DNA-based molecular devices in diabetes management?Natural material adsorbed onto a polymer to enhance immune function.Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord.PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo.Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.Oral insulin delivery: existing barriers and current counter-strategies.Simple Protein Modification Using Zwitterionic Polymer to Mitigate the Bioactivity Loss of Conjugated Insulin.Activity and stability of urease entrapped in thermosensitive poly(N-isopropylacrylamide-co-poly(ethyleneglycol)-methacrylate) hydrogel.Ascorbate as a pro-oxidant: mild N-terminal modification with vinylboronic acids.Identification of anchor points for chemical modification of a small cysteine-rich protein by using a cysteine scan.In vitro and in vivo efficacy of PEGylated diisopropyl fluorophosphatase (DFPase)Bioinspired nanoarchitectonics as emerging drug delivery systems
P2860
Q30354932-315FF7F5-69A8-4FC0-B19E-A57938308BF2Q30384350-B3553AA0-5CA7-41A8-9A84-D724EA3B2732Q30395368-2C507412-9F01-47B9-96B1-5F51E975E201Q31079820-24228F6A-A471-4B3A-8B52-F1643872C3A3Q33274867-A440B897-6285-40A3-A59B-3B63EEE8EFA0Q33393458-FEA49733-07CB-4811-9DF4-FDD3F7A12BA4Q33560166-D06C04B7-1638-4774-B324-B43D4A451853Q33893033-E1EE80B0-9A08-4481-BBA0-D5CD2055CA9CQ34079647-F653B240-DBE9-4AC5-9742-387047FB7BDEQ34514739-64E97379-FD28-4761-B3D0-EAFC0C071F15Q34829819-407199E7-CDCB-42FD-A846-C485915B04E5Q35062556-EBDBA343-0F2A-497E-88A3-1F5EE33D0F36Q35550996-70CA06A1-C87B-4FB9-93BA-D3922A66C8D2Q35574701-F80A9756-E50D-416E-A16B-E54154F99EE2Q35770576-D7D4FE74-DB78-43DA-A69F-44EC7DC6FE20Q35980733-75B3E9A8-5720-4759-AF33-2680088A3AADQ36897485-9ED792E9-6913-4FE3-AB42-CFAEF17A0FACQ36922266-13B1E97F-D737-4185-890A-90ABE330A7B8Q37039026-14C027AF-D5CE-436F-B7B0-27EC29740324Q37386472-634BA9E1-8720-486D-81D6-E1B9DCF39EBBQ37515001-4420F02C-4985-4EB6-839B-1501B2BBBF2DQ37646752-8C913585-2F35-4A80-AE6A-ABFBF9B0675BQ37790702-B5F55067-61C3-42A7-9C91-6F96FE78AF71Q37828078-A499474F-B6AC-47FF-9904-69DA8512D5A5Q38128590-0F4C168E-12A6-4956-80B0-C7F4067E6C0EQ39023191-EDA61040-9859-4FA8-B659-A05B9B237B81Q40218702-F883FB2F-882E-41D7-8EB9-5B609948DE67Q42059297-B89AB64F-CC8C-49EB-87AD-743DCA2AA651Q45863310-DCDC5B50-480D-4202-8216-B23E03FF100FQ46759580-B4B32854-023E-4A30-8EB5-A17EBACBB500Q46919872-4DB61909-2F52-4E75-BDD2-42FB3A5D1BBAQ48203947-66DAB4A7-3443-4CFE-952A-974018739693Q50777218-E6936296-17FC-4A66-BDB1-F0A9B3A0EAA5Q50903857-6A708F34-CE71-4FFC-866F-E7F6B67FB77DQ51187158-1456837E-F538-47C8-8292-EB5412CCFCCEQ53407192-88945AEB-25E0-41EF-A2B0-08D1871558A4Q57912695-A86232A6-39CD-40D0-AFB0-18E9639C13ACQ59264434-ECE53B47-AB60-44A4-8959-74C3F9DA2731
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Effects of PEG conjugation on insulin properties.
@ast
Effects of PEG conjugation on insulin properties.
@en
Effects of PEG conjugation on insulin properties.
@nl
type
label
Effects of PEG conjugation on insulin properties.
@ast
Effects of PEG conjugation on insulin properties.
@en
Effects of PEG conjugation on insulin properties.
@nl
prefLabel
Effects of PEG conjugation on insulin properties.
@ast
Effects of PEG conjugation on insulin properties.
@en
Effects of PEG conjugation on insulin properties.
@nl
P1476
Effects of PEG conjugation on insulin properties.
@en
P2093
Kenneth D Hinds
Sung Wan Kim
P304
P356
10.1016/S0169-409X(02)00025-X
P407
P577
2002-06-01T00:00:00Z